SCIENTIFIC LITERATURE · MED

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.

Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K, P2B Study Group.

Mov Disord · 2023-10-27

DOI: 10.1002/mds.29642PMID: 37886872

Check source for accessClinical Trial, Phase III; Randomized Controlled Trial; Journal ArticleOriginal source ↗

Research overview

This section identifies the original publication. Follow the source for its authors and journal.

Assess the question within the original study’s scope.

Check the source article for study design and sample details.

An editorially approved findings summary is not yet published for this record.

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.